JP2019513014A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513014A5
JP2019513014A5 JP2018547940A JP2018547940A JP2019513014A5 JP 2019513014 A5 JP2019513014 A5 JP 2019513014A5 JP 2018547940 A JP2018547940 A JP 2018547940A JP 2018547940 A JP2018547940 A JP 2018547940A JP 2019513014 A5 JP2019513014 A5 JP 2019513014A5
Authority
JP
Japan
Prior art keywords
domain
scfv
polypeptide
linker
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018547940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513014A (ja
JP7195927B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021435 external-priority patent/WO2017156178A1/en
Publication of JP2019513014A publication Critical patent/JP2019513014A/ja
Publication of JP2019513014A5 publication Critical patent/JP2019513014A5/ja
Priority to JP2022081366A priority Critical patent/JP7293456B2/ja
Application granted granted Critical
Publication of JP7195927B2 publication Critical patent/JP7195927B2/ja
Priority to JP2023093681A priority patent/JP2023123519A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018547940A 2016-03-08 2017-03-08 誘導性結合タンパク質及びその使用方法 Active JP7195927B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022081366A JP7293456B2 (ja) 2016-03-08 2022-05-18 誘導性結合タンパク質及びその使用方法
JP2023093681A JP2023123519A (ja) 2016-03-08 2023-06-07 誘導性結合タンパク質及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305092P 2016-03-08 2016-03-08
US62/305,092 2016-03-08
PCT/US2017/021435 WO2017156178A1 (en) 2016-03-08 2017-03-08 Inducible binding proteins and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022081366A Division JP7293456B2 (ja) 2016-03-08 2022-05-18 誘導性結合タンパク質及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019513014A JP2019513014A (ja) 2019-05-23
JP2019513014A5 true JP2019513014A5 (cg-RX-API-DMAC7.html) 2020-04-16
JP7195927B2 JP7195927B2 (ja) 2022-12-26

Family

ID=59789722

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018547940A Active JP7195927B2 (ja) 2016-03-08 2017-03-08 誘導性結合タンパク質及びその使用方法
JP2022081366A Active JP7293456B2 (ja) 2016-03-08 2022-05-18 誘導性結合タンパク質及びその使用方法
JP2023093681A Pending JP2023123519A (ja) 2016-03-08 2023-06-07 誘導性結合タンパク質及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022081366A Active JP7293456B2 (ja) 2016-03-08 2022-05-18 誘導性結合タンパク質及びその使用方法
JP2023093681A Pending JP2023123519A (ja) 2016-03-08 2023-06-07 誘導性結合タンパク質及びその使用方法

Country Status (14)

Country Link
US (1) US20180134789A1 (cg-RX-API-DMAC7.html)
EP (1) EP3426689A4 (cg-RX-API-DMAC7.html)
JP (3) JP7195927B2 (cg-RX-API-DMAC7.html)
KR (2) KR102501921B1 (cg-RX-API-DMAC7.html)
CN (1) CN109071667A (cg-RX-API-DMAC7.html)
AU (1) AU2017229687A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018068189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3016165A1 (cg-RX-API-DMAC7.html)
IL (1) IL261432B2 (cg-RX-API-DMAC7.html)
MA (1) MA43816A (cg-RX-API-DMAC7.html)
MX (1) MX2018010824A (cg-RX-API-DMAC7.html)
SG (1) SG11201807548SA (cg-RX-API-DMAC7.html)
TW (2) TW201808990A (cg-RX-API-DMAC7.html)
WO (1) WO2017156178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160671A1 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200115461A1 (en) * 2017-05-03 2020-04-16 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
CN111356700A (zh) * 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
KR102578682B1 (ko) * 2017-11-01 2023-09-13 난트바이오 인코포레이티드 Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
CN110218256B (zh) * 2018-03-02 2020-12-08 广西医科大学 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
CN110218253B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
MX2020012217A (es) * 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
MX2020014290A (es) * 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
EP3833444A1 (en) 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
CA3126707A1 (en) * 2019-01-29 2020-08-06 Gritstone Bio, Inc. Multispecific binding proteins
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
JP2022524337A (ja) * 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
WO2021097060A1 (en) * 2019-11-13 2021-05-20 Harpoon Therapeutics, Inc. Pro immune modulating molecule comprising a clustering moiety
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
CN114829408B (zh) * 2019-12-20 2024-01-26 山东博安生物技术股份有限公司 用于免疫治疗的t细胞双特异性抗体生产中的优化抗cd3臂
US12662535B2 (en) 2020-01-17 2026-06-23 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
EP4090686A4 (en) * 2020-01-17 2024-03-27 Immune Targeting Inc. PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
CN115698072B (zh) 2020-07-01 2023-07-04 山东博安生物技术股份有限公司 抗gpc3抗体,抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
US20240409617A1 (en) 2020-07-03 2024-12-12 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
WO2022040128A2 (en) 2020-08-17 2022-02-24 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
CN116261592A (zh) * 2020-08-18 2023-06-13 昂希莱斯制药公司 经修饰的丝氨酸蛋白酶前蛋白
EP4225786A2 (en) * 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重car-t組成物及び方法
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
EP4319806A1 (en) 2021-04-06 2024-02-14 Takeda Pharmaceutical Company Limited Therapeutic methods using constrained conditionally activated binding proteins
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024104988A1 (en) * 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CN108610421B (zh) 2012-02-27 2022-08-19 阿布林克斯有限公司 Cx3cr1结合多肽
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
PL3122781T3 (pl) * 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
HUE054131T2 (hu) * 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
EP3833444A1 (en) * 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins

Similar Documents

Publication Publication Date Title
JP7490853B2 (ja) 拘束され、条件的に活性化された結合タンパク質
US20210355219A1 (en) Conditionally activated target-binding molecules
JP2023526428A5 (cg-RX-API-DMAC7.html)
JP2021087429A5 (cg-RX-API-DMAC7.html)
CN111315773A (zh) 含有Fc区的条件性活化的结合部分
JP2023540533A (ja) ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
JP7855148B2 (ja) 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
US20240026011A1 (en) Constrained conditionally activated binding proteins
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
US12128102B2 (en) Constrained conditionally activated binding proteins
US20230340159A1 (en) Constrained conditionally activated binding proteins
JP2025511190A5 (cg-RX-API-DMAC7.html)
WO2026024863A2 (en) Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
HK40032913A (en) Constrained conditionally activated binding proteins
RU2020123264A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения